We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study.
AIMS Retrospective analyses from first-line clinical studies in advanced non-small cell lung cancer ( NSCLC ) have reported conflicting results on progression-free survival ( PFS ) and overall survival benefits with the addition of bevacizumab to chemotherapy in elderly patients . Here we report effectiveness and safety outcomes by age subgroup for patients with NSCLC in the ARIES observational cohort study . MATERIAL S AND METHODS ARIES enrolled patients with advanced non-squamous NSCLC who received first-line bevacizumab-containing treatment per physician 's choice . Kaplan-Meier estimates were used to calculate medians and 95 % confidence intervals for PFS and overall survival for patients aged < 65 , ≥65 , < 75 and ≥75 years . RESULTS In total , 1967 patients receiving first-line treatment with bevacizumab and chemotherapy were enrolled .  The median PFS and overall survival values were 6.4 ( 95 % confidence interval = 6.0 - 6.8 ) and 14.2 ( 95 % confidence interval = 12.7 - 15.2 ) months for patients aged < 65 years , respectively , and 6.8 ( 95 % confidence interval = 6.3 - 7.0 ) and 12.1 ( 95 % confidence interval = 11.4 - 13.1 ) months for patients ≥65 years , respectively . For patients < 75 years , the median PFS and overall survival values were 6.6 ( 95 % confidence interval = 6.3 - 6.9 ) and 13.5 ( 95 % confidence interval = 12.6 - 14.5 ) months , respectively , and 6.6 ( 95 % confidence interval = 5.9 - 7.1 ) and 11.6 ( 95 % confidence interval = 10.0 - 12.5 ) months , respectively , for patients ≥75 years . Incidence proportions of bevacizumab-associated adverse events were generally similar across all age groups . CONCLUSIONS Data from the ARIES study suggest that treatment with bevacizumab in combination with chemotherapy is a viable first-line treatment option for elderly bevacizumab-eligible patients with advanced non-squamous NSCLC
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV